EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieKlinische Studie (Phase III)Open Access

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer

Rodney J Ellis, Stephanie L Pugh, James B Yu, Felix Y Feng, Andre A Konski, Robert L Grubb, Robert E Wallace, David J Gladstone, Cynthia Ménard, Joseph A Miccio, Arthur J Frazier, J Daniel Pennington und 19 weitere

JAMA · 2026

DOI: 10.1001/jama.2026.12627 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, 2026. Verfasst von Rodney J Ellis und 30 weiteren Autor:innen. Beteiligte Einrichtung: University South Florida and Tampa General Hospital, Tampa. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Radiotherapy, Intensity-Modulated, Radiation Dose Hypofractionation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest.

Objective

To determine whether stereotactic body radiotherapy (SBRT) was superior to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in terms of patient-reported urinary irritative/obstructive and bowel quality of life and disease-free survival (DFS). Design, Setting, and Participants NRG-GU005 was a phase-3, international, open-label, randomized clinical trial. The study was activated on November 16, 2017, and closed to accrual on June 8, 2022. Date of last follow-up was October 13, 2024. There were 136 centers in Asia, Canada, Europe, and the United States that accrued patients to the study. Patients with localized prostate cancer, clinical stage T1-T2b with Gleason 3 + 4 (grade group 2) and prostate-specific antigen (PSA) level less than 20 ng/mL or Gleason 3 + 3 (grade group 1) and PSA level 10 to 20 ng/mL were eligible. Intended accrual of 692 patients provided reductions of 8% and 10% in minimal clinically important decline (MCID) frequency for urinary-irritative/obstructive and bowel domains of the Expanded Prostate Cancer Index Composite–26 Item (EPIC-26) instrument at 2 years and greater than 80% power to detect a hazard ratio of 0.62 in DFS.

Interventions

Patients were randomized 1:1 to receive SBRT (36.25 Gy in 5 fractions; n = 353) or MH-IMRT (70 Gy in 28 fractions or 60 Gy in 20 fractions; n =345). Main Outcomes and Measures Primary outcomes were the frequency of an MCID in the urinary irritative/obstructive and bowel domains of the EPIC-26 at 2 years and DFS at 3 years.

Results

A total of 698 patients were randomized. Median age was 68 years; 3% were Asian, 13% Black, and 80% White. Median follow-up was 3.2 years (range, 0-6.5). At 2 years, there was no significant difference in the urinary-irritative domain (35.4% vs 33.7%, P = .68). Urinary incontinence at 1 and 2 years after treatment and sexual function at 1 year after treatment favored SBRT. Fewer grade 3 + 4 genitourinary adverse events occurred in the SBRT vs MH-IMRT group (0.6% vs 2.5%, P = .04). There were significantly fewer MCIDs with SBRT vs MH-IMRT in the bowel domain (34.9% vs 43.8%, P = .03). At 3 years, DFS for MH-IMRT was 92.1% (95% CI, 88.9%-95.2%) vs 88.6% for SBRT (95% CI, 85.2%-92.1%) (1-sided log-rank P < .001). Conclusions and Relevance Stereotactic body radiotherapy using a modest dose prescription improved multiple quality-of-life domains but was not superior to MH-IMRT in terms of DFS. The rate of PSA failure was not significantly improved in the SBRT vs MH-IMRT group. Trial Registration ClinicalTrials.gov Identifier: NCT03367702

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiosurgeryRadiotherapy, Intensity-ModulatedRadiation Dose HypofractionationMaleHumansQuality of LifeAgedDisease-Free SurvivalMiddle AgedProstate-Specific AntigenAged, 80 and overDose Fractionation, Radiation

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • University South Florida and Tampa General Hospital, Tampa.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
  • American College of Radiology, Philadelphia, Pennsylvania.
  • Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
  • University of California, San Francisco.
  • Chester County Hospital, West Chester, Pennsylvania.

Förderung

  • NCI NIH HHS

Zitieren

APA

Ellis, R. J., Pugh, S. L., Yu, J. B., Feng, F. Y., Konski, A. A., Grubb, R. L., Wallace, R. E., Gladstone, D. J., Ménard, C., Miccio, J. A., Frazier, A. J., Pennington, J. D., Michalski, J. M., Spratt, D. E., Martinez, A., Morgan, S. C., Mihai, A., Solanki, A. A., Amjad, A., …, & NRG-GU005 Collaborative Authors (2026). Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer. JAMA. https://doi.org/10.1001/jama.2026.12627

Vancouver

Ellis RJ, Pugh SL, Yu JB, Feng FY, Konski AA, Grubb RL, et al. Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer. JAMA. 2026. doi:10.1001/jama.2026.12627

BibTeX
@article{Ellis2026,
  author = {Ellis, Rodney J and Pugh, Stephanie L and Yu, James B and Feng, Felix Y and Konski, Andre A and Grubb, Robert L and Wallace, Robert E and Gladstone, David J and Ménard, Cynthia and Miccio, Joseph A and Frazier, Arthur J and Pennington, J Daniel and Michalski, Jeff M and Spratt, Daniel E and Martinez, Alvaro and Morgan, Scott C and Mihai, Alina and Solanki, Abhishek Ashok and Amjad, Asim and Straza, Michael W and Delouya, Guila and Schroeder, Thomas M and Marshall, David T and Kapadia, Nirav and Patel, Akshar N and Cescon, Terrence P and El-Gayed, Ali and Yoon, Harold A and Paulus, Rebecca and Sandler, Howard M and NRG-GU005 Collaborative Authors, NRG-GU005 Collaborative Authors},
  title = {Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2026.12627}
}
Kostenlos starten →